MYERS BIGEL’S ERIN BOBAY TO MODERATE WEBINAR ON IMPLICATIONS OF AMGEN V. SANOFI DECISION

Erin Bobay, partner at Myers Bigel, is set to moderate a webinar on key takeaways for intellectual property counsel from the recent Amgen v. Sanofi Supreme Court Case. Erin is joined by panelists Erin M. Daly, director of intellectual property at Arvinas, Inc., and Vineet Kohli, lead counsel and IP director at BlueNalu, Inc., in a discussion of the implications of the Amgen v. Sanofi decision on patent prosecution.

The decision, wherein Sanofi won a patent dispute with Amgen over a class of patents relating to a series of FDA-approved cholesterol-lowering antibody drugs, is expected to impact how patent practitioners approach patent application drafting, patent portfolio preparation and management, freedom-to-operate (FTO) clearance work, and invalidity argument structure, particularly in the life sciences and chemical arts fields. As the Supreme Court deemed the patents in question to be invalid due to lack of enablement, the webinar will provide insight into how this decision may influence patent litigation going forward, long-term implications on invalidity arguments before the US court, and how life sciences and chemical companies and their future approach on FTO risk assessments may be affected.

Erin’s diverse practice area covering the chemical and biotechnology fields, including pharmaceuticals, inorganic and organic chemicals and compositions, cosmetics, nanotechnology, polymers, medical diagnostics, medical treatments, plant and agriculture related technologies, biofuels, and medical devices, positions her to facilitate these conversations regarding the Amgen v. Sanofi decision with expertise.

The webinar will be held on Thursday, October 19, 2023, at 1:00PM EDT [10:00AM PDT], and all registrants will also receive a recording of the webinar. Register to join Erin and the expert panel as they share their perspectives.